Navigation Links
Multikine in Medical News
CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results
...oduct in the country. CEL-SCI already has existing licensing agreements for multikine with Teva Pharmaceuticals and Orient Europharma. Launch of cold 4 d...rehensive immunotherapy that targets newly diagnosed head and neck cancer. multikine is cleared by the FDA and the Canadian regulators for a global Phase III cl......-SCI already has existing licensing agreements for multikine with Teva Pharmaceuticals and Orient Europharma. ...or registering the product in the Territory. Once multikine has been approved, CEL-SCI will be responsible for...reement is consistent with our strategy to license multikine in the emerging markets to share the expenses of b...
CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference
...gave clearance for a Phase III clinical trial with multikine in January 2007 and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcin...a stronger anti-tumor attack on multiple fronts. multikine is also the first immunotherapeutic agent being de...CEL-SCI Corporation Reports Second Quarter 2008 Financial Results
..." About Multikine: In Phase II clinical trials multikine was shown to be safe and well-tolerated, and to im... in January 2007 and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcin...a stronger anti-tumor attack on multiple fronts. multikine is also the first immunotherapeutic agent being de......cess, eliminating a key risk of the pivotal trial. multikine represents a completely novel medicine with blockb...reak the annual billion-dollar sales barrier'. Our multikine was one of the 10 medicines named." The article ...of the highlights include: -- FDA clearance of multikine for Phase III clinical trial in head and neck ...
CEL-SCI Corporation Releases Letter to Shareholders
... Company highlights of 2007: -- FDA clearance of multikine for Phase III clinical trial in head and neck cancer -- Raised U.S. $15 million -- multikine granted Orphan drug designation in U.S. -- Started build-out of manufacturing facility for multikine to support upcoming Phase III study and commer...CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan
...e the go-ahead for a Phase III clinical trial with multikine in January 2007 and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcin... a stronger anti-tumor attack on multiple fronts. multikine is also the first immunotherapeutic agent being de...Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI
... Administration (FDA) gave the go-ahead for a Phase III clinical trial with multikine in January 2007 and granted orphan drug status to multikine as a neoadjuvant therapy of squamous cell carcinoma (cancer) of the head an...New Help for Head and Neck Cancer
...oost the immune system. Patients received the multikine injections for 10 days. Two patients had a complet...e seen with the therapy. The authors conclude multikine injections may be valuable in the treatment of hea...fine the best dosage and mode of administration of multikine in patients with head and neck cancer.” ...Multikine in Medical Technology
VIENNA, Va., July 10 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM ), a late stage cancer immunotherapy company, announced today that Dr. Eyal Talor, CEL-SCI's Senior Vice President of Research and Manufacturing, has been invited to present to the NIH, NCI's Clinical Cent...
VIENNA, Va., Oct. 7 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE: CVM ) announced today that it has entered into a Material Transfer Agreement (MTA) with the National Institutes of Health Clinical Center (NIHCC) and the laboratory of Dr. Francesco M. Marincola, M.D., to investigate the...
VIENNA, Va., Oct. 7 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE: CVM ) announced today that it has entered into a Material Transfer Agreement (MTA) with the National Institutes of Health Clinical Center (NIHCC) and the laboratory of Dr. Francesco M. Marincola, M.D., to investigate the...
CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
Biomedical Real Estate Group Backs Construction of Facility VIENNA, Va., Aug. 14 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM ) announced today that it has entered into an agreement with a biomedical real estate group under which CEL-SCI acquires long term use of a dedicated...CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
Partner to Make Direct Investment in CEL-SCI VIENNA, Va., Nov. 3 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE: CVM ) announced today that it has expanded its exclusive licensing agreement for Multikine(R) with Orient Europharma Co., Ltd. ("Orient Europharma"), a leading pharmaceutica...CEL-SCI Presents Long-Term Cancer Survival Data With Multikine
Multikine Improves Overall Survival by 33% 3.5 Years Post Surgery VIENNA, Va., May 21, 2007 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION announced today that its cancer drug Multikine(R) was shown to significantly increase long term overall survival in a Phase II study of head and neck cancer pat...CEL-SCI Corporation Releases Letter to Shareholders
...ncer Drug Multikine: In Phase II clinical trials multikine was shown to be safe and well-tolerated, and to im...n the go-ahead for a Phase III clinical trial with multikine and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcin...CEL-SCI Corporation Releases Letter to Shareholders
... Teva will participate in and pay for part of the multikine Phase III trial. We extended our multikine licensing agreement with Orient EuroPharma of Ta... our Phase III trial. multikine was named one of 10 future blockbuster drugs by M...CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
... 8, 2008. This dedicated facility will produce the multikine that will be used for CEL-SCI's pivotal Phase III ...ne. We are now in the home stretch. Having our own multikine dedicated manufacturing facility gives us control ... our product development." CEL-SCI is developing multikine for approval as a first line indication in head an...Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
... Administration (FDA) gave the go-ahead for a Phase III clinical trial with multikine in January 2007 and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head ...CEL-SCI Corporation Reports First Quarter Financial Results
...ncer Drug Multikine: In Phase II clinical trials multikine was shown to be safe and well-tolerated, and to im... in January 2007 and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcin...is currently building a manufacturing facility for multikine close to Baltimore, MD. Upon completion of the fac...Multikine in Biological News
...t cold temperatures.
"We developed this unique cold fill technology over the course of many years and built this new facility for our cancer drug multikine at a cost of about $22 million because we had not been able to find a company that could do a true 4 degrees Celsius cold fill for us. The best they ...
Multikine in Biological Technology
CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
VIENNA, Va., Aug. 19 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM ) announced today that it has entered into an exclusive licensing agreement with Teva Pharmaceutical Industries Ltd. (Teva), a leading global pharmaceutical company, under which CEL-SCI has granted Teva an exclusive...CEL-SCI Corporation Releases Letter to Shareholders
...facturing. This facility was built to manufacture multikine for the Phase III trial and sale thereafter. Due ...ng anywhere else. This means that we can fill our multikine into vials in a completely sterile manner not only... pharmaceutical/biotechnology drug industry. multikine cancer therapy: We believe that the most cri...CEL-SCI Signs Definitive Agreement to Raise $5 Million in Registered Direct Offering
...eration of our H1N1 swine flu work and the validation of our manufacturing facility for contract manufacturing services and to produce our cancer drug multikine for the planned Phase III clinical trial." The securities described above are being offered by CEL-SCI Corporation pursuant to a registration sta......ntigen specificity with immune response modulation. CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is multikine which is being readied for a global Phase III trial. The Company has operations in Vienna, Virginia, and Baltimore, Maryland. When used in this...
...t cold temperatures. "We developed this unique cold fill technology over the course of many years and built this new facility for our cancer drug multikine at a cost of about $22 million because we had not been able to find a company that could do a true 4 degrees Celsius cold fill for us. The best they ...
CEL-SCI Corporation Announces 2008 Financial Results
... fiscal 2008 in preparing for our pivotal trial of multikine for head and neck cancer. Expenditures for 2009 ar...sh expenditures. In Phase II clinical trials multikine was shown to be safe and well-tolerated, and to im...e the go-ahead for a Phase III clinical trial with multikine in January 2007 and granted orphan drug status to...CEL-SCI Corporation Releases Letter to Shareholders
...people had expected and clearly make our non-toxic multikine cancer product even more important to develop. Se... Organization (BIO) which would help CEL-SCI bring multikine to market faster. Last, what percentage of people...er I also want to review the general status of our multikine cancer drug: 1. In the last few months we...Updated Pictures of CEL-SCI Manufacturing Facility Available Online
...ng and FDA cleared Phase III clinical trial, as well as commercial sale, of multikine as a first line indication in treatment naive head and neck cancer patients...h other potential partners are ongoing. In Phase II clinical trials multikine was shown to be safe and well-tolerated, eliminate all of the tumor in 12% ...CEL-SCI Takes Delivery of New Manufacturing Facility
...y, located in the Baltimore area, will produce the multikine that will be used for CEL-SCI's pivotal Phase III ...ne. We are now in the home stretch. Having our own multikine dedicated manufacturing facility gives us control ...n line for manufacturing." CEL-SCI is developing multikine for approval as a first line indication in head an...CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
...g facility and starting the Phase III study of our multikine cancer drug. Some additional funds were spent on o..." About Multikine: In Phase II clinical trials multikine was shown to be safe and well-tolerated, and to im... in January 2007 and granted orphan drug status to multikine in the neoadjuvant therapy of squamous cell carcin...Other TagsOther Contents
CeleryMusselPaprikaBassBlackAvocadoWoolEpitheliaDanderAustParakeetBudgerigarEpidermalsandrostanemandelic
(Date:5/23/2013)... 23, 2013 Elegance for a woman takes on ... her taste, her intrigue can often be found in the mystery ... a woman's soul is through her eyes. It is also ... is! That is why the elegance of a woman can be ... Women today, more than any other time, utilize eyewear to not ...
(Date:5/23/2013)... 2013 Aero Fulfillment Services, a national ... NewWave Biosciences to be the sole fulfillment provider for ... , Brad Cole, CEO New Wave Biosciences said, ... their central location, e-commerce experience with both of our ... end-to-end solution that will expand as our distribution grows.” ...
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 Each month ... most innovative and stylish eco-friendly hybrids and electric cars. Nowhere ... in Los Angeles, the symbolic green car capital. Thankfully this ... Car Tour ride and drive back to Dwell on ... event. , During the first two days of Dwell ...
(Date:5/23/2013)... York (PRWEB) May 23, 2013 Maintaining ... today launches its Summer Health Campaign. Kicking off in ... to offering a luxury bed for everyone and to ... overall health and well-being. , May is Better Sleep ... by the Better Sleep Council due to the Centers ...
(Date:5/23/2013)... two-thirds of patients with high-risk neuroblastoma a common tumor ... cured using tumor-killing cancer drugs. A study published by ... Chemistry & Biology reveals a new genomic approach ... by causing cancer cells to differentiate, or convert from ... screening method, the researchers identified a compound that causes ...
Breaking Medicine News(10 mins):Health News:Dolabany Eyewear Adds Feminine Flare to Women's Designer Eyewear with 2013 New Release of Adelina by Best Image Optical, Inc. 2Health News:NewWave Biosciences Chooses Aero Fulfillment for e-Commerce Distribution of New Product to Reduce Inflammation 2Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 2Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 3Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 4Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 5Health News:DUXIANA®, Quality Bed Innovator, Celebrates Better Sleep Month and Launches Summer Health Campaign 2Health News:New screening approach uncovers potential alternative drug therapies for neuroblastoma 2[0] Dolabany Eyewear Adds Feminine Flare to Women's Designer Eyewear with 2013 New Release of Adelina by Best Image Optical, Inc.[0] NewWave Biosciences Chooses Aero Fulfillment for e-Commerce Distribution of New Product to Reduce Inflammation[0] Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013[0] DUXIANA®, Quality Bed Innovator, Celebrates Better Sleep Month and Launches Summer Health Campaign[0] New screening approach uncovers potential alternative drug therapies for neuroblastoma
(Date:5/23/2013)... In an age when microbial pathogens are growing ... down infection, a team of Wisconsin scientists has synthesized ... the bacteria that cause staph infections. , Writing online ... , a group led by University of Wisconsin-Madison chemistry ... the "quorum sensing" behavior of Staphylococcus aureus , ...
(Date:5/22/2013)... to improve durability in fuel cell powered buses, ... discovered links between electrode degradation processes and bus ... effects of electrode degradation stressors in the operating ... , The findings of the study, led by ... in a long-term study at Burnaby-based Ballard Power ...
(Date:5/22/2013)... 2013)The omega 3 fatty acids in fish oil have ... so that the American Heart Association currently recommends eating ... fatty varieties rich in omega 3s. However, the mechanism ... a new study, scientists led by Jason R. Carter ... by providing evidence that fish oil might specifically counteract ...
Breaking Biology News(10 mins):University of Wisconsin chemists find new compounds to curb staph infection 2Tests lead to doubling of fuel cell life 2Fish oil may help the heart beat mental stress 2| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |